Exact Sciences Corp. [EXAS] stock is trading at $70.27, down -0.44%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The EXAS shares have lost -0.50% over the last week, with a monthly amount glided 2.24%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Exact Sciences Corp. [NASDAQ: EXAS] stock has seen the most recent analyst activity on August 28, 2024, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $75. Previously, Scotiabank started tracking the stock with Sector Outperform rating on June 27, 2024, and set its price target to $70. The Benchmark Company upgraded its rating to a Buy but stick to its price target of $91 on January 02, 2024. Guggenheim initiated its recommendation with a Buy and recommended $90 as its price target on December 14, 2023. Wolfe Research started tracking with a Outperform rating for this stock on December 13, 2023, and assigned it a price target of $95. In a note dated October 10, 2023, Piper Sandler upgraded an Overweight rating on this stock but restated the target price of $90.
Exact Sciences Corp. [EXAS] stock has fluctuated between $40.62 and $79.62 over the past year. Currently, Wall Street analysts expect the stock to reach $90 within the next 12 months. Exact Sciences Corp. [NASDAQ: EXAS] shares were valued at $70.27 at the most recent close of the market. An investor can expect a potential return of 28.08% based on the average EXAS price forecast.
Analyzing the EXAS fundamentals
Exact Sciences Corp. [NASDAQ:EXAS] reported sales of 2.61B for the trailing twelve months, which represents a growth of 12.41%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.07%, and Net Profit Margin reading is -0.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.06 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.81.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 69.15 points at the first support level, and at 68.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 71.41, and for the 2nd resistance point, it is at 72.55.
Ratios To Look Out For
For context, Exact Sciences Corp.’s Current Ratio is 2.17. Also, the Quick Ratio is 1.98, while the Cash Ratio stands at 0.79. Considering the valuation of this stock, the price to sales ratio is 4.97, the price to book ratio is 4.06.
Transactions by insiders
Recent insider trading involved Baranick Brian, EVP, GM, Precision Oncology, that happened on Oct 08 ’24 when 929.0 shares were sold. Officer, Baranick Brian completed a deal on Oct 08 ’24 to buy 929.0 shares. Meanwhile, EVP, GM, Precision Oncology Baranick Brian sold 929.0 shares on Sep 18 ’24.
